Century Therapeutics
Developing novel allogeneic iPSC-derived natural killer (NK) and T cell products with the potential to overcome many limitations of earlier generation cell therapies. Learn more
Launch date
Employees
Market cap
CAD185m
Enterprise valuation
(CAD6m) (Public information from Sep 2024)
Share price
$1.7 IPSC
Philadelphia Pennsylvania (HQ)
Authorizing premium user...